RxDoctor Payments Data

Mary Hartnett, MD

Retina Specialist · Stanford, CANPI 1871507020

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $59,570 of the $72,893 with a category attached, or 81.7%. Johnson & Johnson accounts for 92.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $51,797 and has fallen 80.7% since, to $9,990 in 2025.

$72,893in general payments, 2019–2025

Across 67 payments — averaging $1087.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$67K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
  • Carl Zeiss Meditec, Inc.$206
  • Dutch Ophthalmic, USA$119
  • Janssen Global Services, LLC$114
  • Genentech, Inc.$12
$16,400in research payments, 2019–2025

Across 3 payments — averaging $5466.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$16K

What the payments were for

  • Consulting fees$59,57082%
  • Speaking & faculty fees$5,0007%
  • Travel & lodging$6,7619%
  • Food & beverage$1,5622%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,893 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$7,731
Medicare patients
19
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other retina specialist in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →